Publications by authors named "C Shubert"
Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, in part resulting from cellular heterogeneity that supports overall tumorigenicity. Cancer associated fibroblasts (CAF) are key determinants of PDAC biology and response to systemic therapy. While CAF subtypes have been defined, the effects of patient-specific CAF heterogeneity and plasticity on tumor cell behavior remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- Improved surgical techniques and therapy have enabled more patients with oligometastatic colorectal cancer to qualify for surgery, but many still experience recurrence, which varies by site and outcome.
- A study of 195 patients who had liver metastasis resection revealed that the one-year recurrence-free survival was 46%, while overall survival rates were high at 95% for the same period; several prognostic factors for worse outcomes were identified.
- The findings highlight the need for further research to pinpoint patients at increased risk of recurrence, potentially guiding additional preventive treatment strategies.
Article Synopsis
- Researchers developed a new method for matching chemotherapy regimens to pancreatic cancer patients based on chemosensitivity data from patient-derived organoids (PDOs).
- In a study involving PDOs from 95 patients, the method successfully matched 91% of the organoids to standard chemotherapeutics and showed that well-matched patients had significantly better clinical outcomes, such as reduced tumor markers and improved survival rates.
- The findings suggest that using PDO pharmacotyping to customize chemotherapy could lead to better treatment strategies and outcomes for patients with pancreatic ductal adenocarcinoma.
Article Synopsis
- A study at Johns Hopkins Hospital compared outcomes of patients who received neoadjuvant immunotherapy before surgery with those who had upfront resection; 36 of the 92 patients received the immunotherapy.
- The results showed that patients who underwent neoadjuvant immunotherapy had similar resection margins and recurrence-free survival rates compared to those who had upfront surgery, suggesting that this approach might help high-risk patients achieve comparable outcomes.
Background: Minimally invasive pancreatic surgery (MIPS), when selectively utilized, has been shown to hasten recovery with outcomes comparable to open approaches, but access may not be equitable. This study explored variation in utilization of MIPS for pancreatic cancer.
Methods: The National Cancer Database was queried to identify patients diagnosed with a primary pancreatic neoplasm from 2010 to 2020.